New PET scan could spot liver cancer spread more clearly
NCT ID NCT05176223
First seen Feb 05, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This phase II trial at Mayo Clinic tested whether a special PET scan using 68Ga-PSMA can better detect and track advanced liver cancer that has spread. The radioactive tracer attaches to a protein found on liver cancer cells, making them visible on the scan. The study enrolled 29 adults with advanced liver cancer not treatable by surgery, aiming to see if this imaging improves diagnosis and management compared to standard methods.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Gallium Ga 68 Gozetotide (68Ga-PSMA)
What this could lead to
If successful, this imaging method could help doctors better detect and monitor advanced liver cancer, potentially leading to more personalized treatment decisions.
What could go wrong
This is a small, early-phase study with only 29 participants, so results may not apply to all patients. The imaging technique is still experimental and not yet standard practice.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.